NASDAQ
AXON

Axovant Sciences Ltd

Aerospace & Defense
Industrials

Prices are adjusted according to historical splits.

Axovant Sciences Ltd Stock Price

Vitals

Today's Low:
$210.27
Today's High:
$213.13
Open Price:
$210.83
52W Low:
$83.01
52W High:
$229.95
Prev. Close:
$213.19
Volume:
367701

Company Statistics

Market Cap.:
$14.27 billion
Book Value:
18.992
Revenue TTM:
$1.28 billion
Operating Margin TTM:
7.67%
Gross Profit TTM:
$728.64 million
Profit Margin:
10.76%
Return on Assets TTM:
2.56%
Return on Equity TTM:
10.87%

Company Profile

Axovant Sciences Ltd had its IPO on 2001-06-07 under the ticker symbol AXON.

The company operates in the Industrials sector and Aerospace & Defense industry. Axovant Sciences Ltd has a staff strength of 2,821 employees.

Stock update

Shares of Axovant Sciences Ltd opened at $210.83 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $210.27 - $213.13, and closed at $211.93.

This is a -0.59% slip from the previous day's closing price.

A total volume of 367,701 shares were traded at the close of the day’s session.

In the last one week, shares of Axovant Sciences Ltd have slipped by -1.61%.

Axovant Sciences Ltd's Key Ratios

Axovant Sciences Ltd has a market cap of $14.27 billion, indicating a price to book ratio of 10.0288 and a price to sales ratio of 11.2002.

In the last 12-months Axovant Sciences Ltd’s revenue was $1.28 billion with a gross profit of $728.64 million and an EBITDA of $123.28 million. The EBITDA ratio measures Axovant Sciences Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Axovant Sciences Ltd’s operating margin was 7.67% while its return on assets stood at 2.56% with a return of equity of 10.87%.

In Q1, Axovant Sciences Ltd’s quarterly earnings growth was a negative -19.7% while revenue growth was a positive 33.8%.

Axovant Sciences Ltd’s PE and PEG Ratio

Forward PE
63.2911
Trailing PE
102.7527
PEG
2.86

Its diluted EPS in the last 12-months stands at $1.88 per share while it has a forward price to earnings multiple of 63.2911 and a PEG multiple of 2.86. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Axovant Sciences Ltd’s profitability.

Axovant Sciences Ltd stock is trading at a EV to sales ratio of 11.1888 and a EV to EBITDA ratio of 178.6723. Its price to sales ratio in the trailing 12-months stood at 11.2002.

Axovant Sciences Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$3.01 billion
Total Liabilities
$616.13 million
Operating Cash Flow
$-72674000.00
Capital Expenditure
$8.64 million
Dividend Payout Ratio
0%

Axovant Sciences Ltd ended 2024 with $3.01 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $3.01 billion while shareholder equity stood at $1.40 billion.

Axovant Sciences Ltd ended 2024 with $7.98 million in deferred long-term liabilities, $616.13 million in other current liabilities, 1000.00 in common stock, $302.16 million in retained earnings and $44.98 million in goodwill. Its cash balance stood at $263.41 million and cash and short-term investments were $1.09 billion. The company’s total short-term debt was $0 while long-term debt stood at $674.72 million.

Axovant Sciences Ltd’s total current assets stands at $2.05 billion while long-term investments were $35.58 million and short-term investments were $829.94 million. Its net receivables were $596.76 million compared to accounts payable of $65.99 million and inventory worth $220.27 million.

In 2024, Axovant Sciences Ltd's operating cash flow was $-72674000.00 while its capital expenditure stood at $8.64 million.

Comparatively, Axovant Sciences Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$211.93
52-Week High
$229.95
52-Week Low
$83.01
Analyst Target Price
$247.79

Axovant Sciences Ltd stock is currently trading at $211.93 per share. It touched a 52-week high of $229.95 and a 52-week low of $229.95. Analysts tracking the stock have a 12-month average target price of $247.79.

Its 50-day moving average was $195.66 and 200-day moving average was $197.42 The short ratio stood at 1.09 indicating a short percent outstanding of 0%.

Around 606.6% of the company’s stock are held by insiders while 7740.2% are held by institutions.

Frequently Asked Questions About Axovant Sciences Ltd

The stock symbol (also called stock or share ticker) of Axovant Sciences Ltd is AXON

The IPO of Axovant Sciences Ltd took place on 2001-06-07

Similar Industry Stocks (Aerospace & Defense)

Last Price
Chg
Chg%
$9.25
-1.75
-15.91%
$234
0
0%
$0.57
-0.01
-0.94%
$463.75
-25.35
-5.18%
$1.3
0
+0.05%
$187.9
2.9
+1.57%
Arvind Limited (500101)
$158.65
-13.3
-7.73%
111 Inc (YI)
$2.59
-0.04
-1.53%
$5.95
-0.19
-3.09%
$27
0.1
+0.37%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Axon Enterprise, Inc. develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. Its products include TASER 7, TASER X26P, TASER X2, TASER Consumer devices, and related cartridges; on-officer body cameras, Axon Fleet in-car systems, and other devices; Axon Evidence digital evidence management software-as-a-service; Axon Signal enabled devices, as well as hardware extended warranties; and Axon docks, cartridges, and batteries. It sells its products through its direct sales force, distribution partners, online store, and third-party resellers. Axon Enterprise, Inc. has a strategic partnership with Fusus, Inc. to expand the capabilities of Axon Respond and the Fusus Real-Time Crime Center in the Cloud solution to provide agencies real-time operations situational awareness. The company was formerly known as TASER International, Inc. and changed its name to Axon Enterprise, Inc. in April 2017. Axon Enterprise, Inc. was incorporated in 1993 and is headquartered in Scottsdale, Arizona.

Address

17800 North 85th Street, Scottsdale, AZ, United States, 85255